Omnicell (OMCL) to Post Quarterly Earnings on Thursday

Omnicell (NASDAQ:OMCL) will likely be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of $0.48 per share and revenue of $310.2130 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The firm had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same quarter in the previous year, the firm posted $0.26 earnings per share. The company’s revenue was up 14.9% on a year-over-year basis. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Omnicell Stock Up 1.2%

Shares of OMCL opened at $41.49 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50. Omnicell has a 52 week low of $28.09 and a 52 week high of $55.00. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of 94.30, a PEG ratio of 1.06 and a beta of 0.96. The stock has a fifty day moving average of $42.37 and a 200-day moving average of $41.33.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares in the company, valued at $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently made changes to their positions in OMCL. Mercer Global Advisors Inc. ADV boosted its holdings in Omnicell by 51.2% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,573 shares of the company’s stock valued at $615,000 after acquiring an additional 4,599 shares during the last quarter. State of Tennessee Department of Treasury increased its position in Omnicell by 15.1% during the 4th quarter. State of Tennessee Department of Treasury now owns 26,504 shares of the company’s stock valued at $1,285,000 after purchasing an additional 3,470 shares during the period. EP Wealth Advisors LLC bought a new position in Omnicell during the 4th quarter worth approximately $307,000. Fuller & Thaler Asset Management Inc. bought a new position in Omnicell during the 4th quarter worth approximately $610,000. Finally, Empowered Funds LLC bought a new position in Omnicell during the 4th quarter worth approximately $274,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Craig Hallum reaffirmed a “buy” rating and issued a $55.00 target price on shares of Omnicell in a report on Wednesday, April 29th. Zacks Research lowered Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. KeyCorp boosted their price target on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Finally, Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $59.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.